Vilitigo
Conditions
Interventions
Oral Compound Glycyrrhizin Group (Progressive vitiligo patients):Oral compound glycyrrhizin
Oral Prednisone Group (Progressive vitiligo patients):Oral prednisone
Stable vitiligo patients:None
Progressive vitiligo patients:None
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
2 Years to 16 Years
Inclusion criteria
Inclusion criteria: (1) The patient was diagnosed as vitiligo by the presence of one or more localized depigmented spots on the body, which showed bright white fluorescence under Wood's lamp. Progressive stage: According to vitiligo disease activity score (VIDA), clinical characteristics, isomorphism reaction, Wood's lamp examination results --?VIDA score: total score >1 was defined as progressive stage, =4 was defined as rapid progressive stage; ? Clinical features: the appearance of blurred edge of skin lesions, inflammatory vitiligo, trichromatic vitiligo, confetti vitiligo or hypopigmented vitiligo can be judged as advanced vitiligo. (3) Isomorphous reaction: leukoplakia appeared at the site of skin injury within one year, and the injury mode could be physical or chemical; ?Wood's lamp examination results: the boundary was not clear, and the area of skin lesions under Wood's lamp was greater than that of visual inspection, suggesting that the disease was progressive. If any one of the above four criteria is met, disease progression can be considered. Stable phase: ?VIDA score was 0; ? Clinical features: leukoplakia was porcelain white with clear edge or hyperpigmentation; ? No isomorphous reaction (=1 year); ?Wood lamp: the lesion was white with clear boundary, and the lesion area under Wood lamp was less than the visual area. At least two of the above four factors indicated stable stage. Both laser confocal scanning microscopy and dermoscopy can be used to assist the diagnosis. (2) Patients had not received systemic glucocorticoids or immunomodulators within 3 months before enrollment; (3) Age 2-16; (4) Those understand and voluntarily sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) patients with severe hypertension and diabetes; (2) patients with active peptic ulcer disease or infection; (3) patients with fracture, trauma repair period and/or definite history of osteoporosis; (4) patients with severe heart and lung diseases, liver and kidney insufficiency, coagulopathy and/or tumor, and hypokalemia; (5) other hypopigmented skin diseases such as amelanotic nevus, pityriasis alba, inflammatory hypopigmented macula, pietrosis, idiopathic hypopigmented macula and anemic nevus; (6) patients with mental disorders; (7) Patients who have recently participated in other clinical studies;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VASI score;time to achieve arrest of disease progression;changes of clinical sign ; | — |
Secondary
| Measure | Time frame |
|---|---|
| VitiQOL;Adverse reaction records; | — |
Countries
China
Contacts
Public ContactLi Zhang
Huashan Hospital, Fudan University
Outcome results
None listed